Bethesda, MD (PRWEB) March 09, 2016
ImMAGE Biotherapeutics Corporation, an affiliate of PepVax, Inc., has raised an initial seed round of $500,000 to lay an operational foundation and fund research of a protein-targeted drug therapy designed to treat triple-negative breast cancer (TNBC).
“We are driven by the need to find a better way to target tumors expressing the MAGE-A antigen as well as favorable market conditions,” Chief Operating Officer Mahesh Narayanan said. “Since the company’s inception in 2015, our team of researchers has prioritized meeting and exceeding all of our key development milestones.”
Current funding has given ImMAGE Biotherapeutics the opportunity to build an infrastructure and a larger operational footprint, while expanding the company’s total research capacity. Primary lab facilities are based at Howard University in Washington, DC.
The investor, Coventry International of Hong Kong, has recognized the ability to influence the future of treating breast cancer.
“The technology that is being developed for the treatment of TNBC is beyond the cutting edge in its design,” Chief Scientific Officer Anton Dormer, PhD. said. “The company is dedicated to providing therapeutics that will increase human longevity and lead to enhancing women’s health in the near term.”
The early-stage company is one of the leaders in protein-targeted immunotherapy with a proprietary approach to treating tumors. ImMAGE Biotherapeutics is promising to deliver an alternative method to chemotherapy or surgical treatment of cancer. Breast cancer patients are one of the fastest growing patient populations in the country, with very little effective late-stage therapies.
Currently, ImMAGE Biotherapeutics has eight promising candidates, which they expect to take into animal trials this spring. Future funding will also accelerate these candidates through the research and development phase.
About ImMAGE Biotherapeutics
Founded in 2015, ImMAGE Biotherapeutics, an affiliate of PepVax, Inc., is currently developing multiple viable candidates to treat triple-negative breast cancer (TNBC). The company’s core group of researchers, based in Washington, DC and Bethesda, MD, are currently moving from in-vitro trials to animal testing.
The team’s work is rooted in the idea that the human immune system, when manipulated, can heal mutations or growing tumor cells. The immunotherapy market is expected to grow to $17.4 billion and
ImMAGE Biotherapeutics’ treatment can be applied to 60 percent of cancer patients. For more information, please visit http://www.immagebio.com.